Here's Why You Should Hold Avantor Stock in Your Portfolio for Now
AVTR's product breadth, digital upgrades and new pharma wins support growth, though VWR Distribution & Services remains a challenge.
AVTR - Avantor, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$9.10
DETAILS
HIGH:
$11.00
LOW:
$7.00
MEDIAN:
$9.50
CONSENSUS:
$9.10
DOWNSIDE:
13.83%
Stock News
Avantor® to Report Second Quarter 2026 Earnings on Wednesday, July 29, 2026
RADNOR, Pa., July 1, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its second quarter 2026 financial results before the market opens on Wednesday, July 29, and will hold a conference call to discuss the results on the same day at 8:00 a.m.
Why Is Avantor (AVTR) Up 13% Since Last Earnings Report?
Avantor (AVTR) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Hold Avantor Stock in Your Portfolio for Now
AVTR's product breadth, digital upgrades and new pharma wins support growth, though VWR Distribution & Services remains a challenge.
Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
RADNOR, Pa., May 19, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that Gerard (Jerry) Porreca has joined the company as Executive Vice President, Quality and Regulatory.
Avantor Q1 Earnings & Revenues Beat Estimates, Margins Decline
AVTR benefits from stable Q1 revenues and improving demand trends, though margin pressure and volume softness weigh on profitability.
Avantor Q1 2026 Earnings Review: Stabilization Emerging, But Recovery Not Yet Visible
Avantor, Inc. reported a slight beat on 1Q26 EPS and revenue, but underlying organic growth and margins remain under pressure. Negative organic growth, margin compression, and subdued cash flow signal only early stabilization, not a confirmed recovery, especially in the VWR segment. Management reaffirmed 2026 guidance and expects sequential improvement, but the recovery is execution-dependent and gradual, with margins likely to remain below historical peaks.
Avantor, Inc. (AVTR) Q1 2026 Earnings Call Transcript
Avantor, Inc. (AVTR) Q1 2026 Earnings Call Transcript
Avantor, Inc. (AVTR) Q1 Earnings and Revenues Top Estimates
Avantor, Inc. (AVTR) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.23 per share a year ago.
Avantor® Reports First Quarter 2026 Results
Net sales of $1,581 million Net income of $43 million; Adjusted EBITDA of $219 million Diluted GAAP EPS of $0.06; adjusted EPS of $0.17 Operating cash flow of $59 million; free cash flow of $25 million Reaffirms FY 2026 guidance RADNOR, Pa., April 29, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first fiscal quarter ended March 31, 2026.
Avantor® Announces Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer
RADNOR, Pa., April 23, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that Ludovic Brellier will join the company as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer on May 1, 2026.
Avantor Expands Masterflex Portfolio to Streamline Bioprocessing
AVTR expands Masterflex across its fluid handling portfolio, aiming to streamline workflows and boost scalable bioprocessing adoption.
Kuehn Law Encourages Investors of Avantor, Inc. to Contact Law Firm
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Avantor, Inc. (NYSE: AVTR) breached their fiduciary duties to shareholders.
Avantor® Unifies Masterflex® Portfolio to Streamline Fluid Management from R&D to Bioprocess Manufacturing
Portfolio now includes standard, configurable, and engineered-to-order peristaltic pumps, single-use assemblies, and systems for R&D through high-volume manufacturing Company to attend INTERPHEX 2026 in New York City from April 21-23 RADNOR, Pa., April 21, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to the life sciences and advanced technology industries, today announced the expansion of its Masterflex brand across its fluid handling portfolio, bringing together standard, configurable, and engineered-to-order peristaltic pumps, single-use assemblies, and systems.
Longleaf Partners Fund Q1 2026 Contributors And Detractors
During the quarter, we had no new purchases and exited three holdings: Louisiana-Pacific, PayPal and Walt Disney. CNH, a leading global agriculture and construction equipment manufacturer, was a contributor for the quarter. Life-sciences company Avantor detracted for the quarter.
Avantor Stock Up as New Lab Capabilities Improve Biopharma Support
AVTR stock gains after expanding U.S. lab capabilities, boosting biopharma support, streamlining testing and strengthening supply chain efficiency.
Avantor® Enhances U.S. Biomanufacturing Infrastructure with Expanded Stability and Microbial Testing Facility
St. Louis site strengthens integrated support for biopharma manufacturing RADNOR, Pa., April 13, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced the expansion of its North American quality control capabilities with the addition of advanced microbial and stability testing at its St. Louis manufacturing site.
Comparing First Choice Healthcare Solutions (OTCMKTS:FCHS) and Avantor (NYSE:AVTR)
First Choice Healthcare Solutions (OTCMKTS:FCHS - Get Free Report) and Avantor (NYSE: AVTR - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations. Insider and Institutional Ownership 95.1% of Avantor
Avantor® to Report First Quarter 2026 Earnings on Wednesday, April 29, 2026
RADNOR, Pa., April 3, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its first quarter 2026 financial results before the market opens on Wednesday, April 29, and will hold a conference call to discuss the results on the same day at 8:00 a.m.
Avantor® Announces CFO Transition
RADNOR, Pa., April 1, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that Executive Vice President and Chief Financial Officer (CFO), R.
Price Targets
Avantor price target raised to $10.50 from $8 at Evercore ISI
$10.50
(was $10.39)
Evercore ISI
Avantor resumed with a Market Perform at Bernstein
$10.50
(was $10.08)
Bernstein
Avantor price target raised to $8 from $7 at Barclays
$8.00
(was $9.43)
UBS
Avantor assumed with Underperform from Peer Perform at Wolfe Research
$7.00
(was $9.19)
Wolfe Research
Avantor resumed with a Sector Perform at RBC Capital
$9.00
(was $7.94)
RBC Capital
Avantor price target lowered to $7 from $8.50 at Barclays
$7.00
(was $8.18)
Barclays
Avantor price target lowered to $10 from $12 at Morgan Stanley
$10.00
(was $9.38)
Morgan Stanley
Avantor price target lowered to $10.50 from $13 at UBS
$10.50
(was $9.35)
Dan Leonard
·
UBS
Avantor price target lowered to $10 from $12 at Stifel
$10.00
(was $9.24)
Stifel Nicolaus
Avantor price target lowered to $8 from $9 at Jefferies
$8.00
(was $9.24)
Tycho Peterson
·
Jefferies
Avantor price target lowered to $9 from $12 at Barclays
$9.00
(was $9.64)
Barclays
Avantor price target lowered to $11 from $15 at Baird
$11.00
(was $9.64)
Robert W. Baird
Avantor price target lowered to $10 from $12 at Evercore ISI
$10.00
(was $9.31)
Vijay Kumar
·
Evercore ISI
Avantor downgraded to In Line from Outperform at Evercore ISI
$12.00
(was $11.46)
Evercore ISI
Jefferies Downgrades Avantor Inc. (AVTR) to Underperform
$9.00
(was $11.20)
Tycho Peterson
·
Jefferies
Avantor downgraded to Equal Weight from Overweight at Barclays
$12.00
(was $11.58)
Luke Sergott
·
Barclays
Avantor downgraded to Neutral from Overweight at JPMorgan
$12.00
(was $11.58)
UBS
Avantor price target raised to $15 from $13 at Barclays
$15.00
(was $13.67)
Luke Sergott
·
Barclays
Avantor price target lowered to $12 from $14 at Stifel
$12.00
(was $11.30)
Stifel Nicolaus
Avantor price target lowered to $14 from $16 at Raymond James
$14.00
(was $11.30)
Raymond James